Low
NA
$162.00/day
| Height | Males | Females |
|---|---|---|
| 150.0 cm | 50.0 kg | 45.5 kg |
| 152.5 cm | 52.3 kg | 47.8 kg |
| 155.0 cm | 54.6 kg | 50.1 kg |
| 157.5 cm | 56.9 kg | 52.4 kg |
| 160.0 cm | 59.2 kg | 54.7 kg |
| 162.5 cm | 61.5 kg | 57.0 kg |
| 165.0 cm | 63.8 kg | 59.3 kg |
| 167.5 cm | 66.1 kg | 61.6 kg |
| 170.0 cm | 68.4 kg | 63.9 kg |
| 172.5 cm | 70.7 kg | 66.2 kg |
| 175.0 cm | 73.0 kg | 68.5 kg |
| 177.5 cm | 75.3 kg | 70.8 kg |
| 180.0 cm | 77.6 kg | 73.1 kg |
| 182.5 cm | 79.9 kg | 75.4 kg |
| 185.0 cm | 82.2 kg | 77.7 kg |
| 187.5 cm | 84.5 kg | 80.0 kg |
| 190.0 cm | 86.8 kg | 82.3 kg |
Therapy of gram negative organisms resistant to gentamicin and tobramycin but susceptible to amikacin (HAP, UTI, other).
As combination therapy for the treatment of some Mycobacteria species (e.g. M. abscessus).
Serum creatinine whenever initiating any aminoglycoside.
Creatinine and trough level should be monitored AT LEAST twice weekly; more often if unstable renal function or addition of nephrotoxic medications.
Trough level should be collected 30 min prior to scheduled dose
Target Trough Level
Once daily/extended interval dosing: < 4 mg/L
Multiple daily dosing: < 4 mg/L
Amikacin Peaks
Are not used in once daily/extended interval regimens.
For multiple daily dosing regimens, peaks not commonly measured but if required are collected 30-60 min after infusion complete
Risk of toxicity with aminoglycosides increases with duration of therapy even if levels are maintained in appropriate therapeutic range. Therapy should be kept to minimum duration appropriate for indication to minimize this risk.
Nephrotoxicity
Less common with once daily dosing.
Avoid concomitant nephrotoxins.
Greater toxicity with longer duration and supratherapeutic trough levels.
Vestibulocochlear toxicity
Irreversible
Audiology testing recommended for prolonged use
Other
Increased nephrotoxicity with:
Amphotericin B
Cyclosporine
Cisplatin
NSAIDS
Contrast dye
Vancomycin
Increased ototoxicity with:
Respiratory paralysis with:
IV Administration
Dilute in 100-250 mL NS or D5W; administer over 30-60 min
EH Prescribing Restrictions
Unrestricted
Pharmacist Reviews Therapy
Community IV Formulary (Metro Region)
YES
See EH Intranet for Full Aminoglycoside dosing policy: PHA-124 Aminoglycoside Antibiotic Monitoring (Adult)
Antimicrobial class: Aminoglycoside
Pregnancy category: D
Average serum half life: 2.5 hours
Biliary penetration: Moderate
CSF penetration: Poor
Lung penetration: Therapeutic
Urine penetration: Therapeutic
